NASDAQ:NBTX Nanobiotix Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nanobiotix S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $19.00 -0.49 (-2.51 %) (As of 01/22/2021 12:00 AM ET) Add Compare Share Today's Range$18.42Now: $19.00▼$19.0050-Day Range N/A52-Week Range N/AVolume7,543 shsAverage Volume38,941 shsMarket Capitalization$633.46 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsHeadlinesSocial Media Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.Read More MarketRank™Overall MarketRank™1.13 out of 5 starsMedical Sector893rd out of 1,925 stocksBiotechnology Industry5th out of 88 stocksAnalyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Nanobiotix. Previous Next 5.0 Community Rank Outperform VotesNanobiotix has received 2 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNanobiotix has received 0 “underperform” votes. (Add your “underperform” vote.)Community SentimentNanobiotix has received 100.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nanobiotix and other stocks. Vote “Outperform” if you believe NBTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NBTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNanobiotix does not currently pay a dividend.Dividend GrowthNanobiotix does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nanobiotix insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nanobiotix are expected to grow in the coming year, from ($1.95) to ($1.71) per share. Previous Next See Top Rated MarketRank™ Stocks Here Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NBTX Previous Symbol CUSIPN/A CIKN/A Webwww.nanobiotix.com Phone33 1 40 26 04 70Employees98 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Outstanding Shares33,340,000Market Cap$633.46 million Next Earnings DateN/A OptionableNot Optionable Receive NBTX News and Ratings via Email Sign-up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Nanobiotix (NASDAQ:NBTX) Frequently Asked Questions Is Nanobiotix a buy right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nanobiotix in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Nanobiotix stock. View analyst ratings for Nanobiotix or view MarketBeat's top 5 stock picks. What stocks does MarketBeat like better than Nanobiotix? Wall Street analysts have given Nanobiotix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nanobiotix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. What is Doug Parker's approval rating as Nanobiotix's CEO? 1,448 employees have rated Nanobiotix CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Nanobiotix's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Nanobiotix's key competitors? Some companies that are related to Nanobiotix include Trillium Therapeutics Inc. (TRIL.TO) (TRIL), Concordia International Corp. (CXR.TO) (CXR), 4D Molecular Therapeutics (FDMT), iTeos Therapeutics (ITOS), PureTech Health (PRTC), Novacyt S.A. (NCYT.L) (NCYT), Oxford Biomedica plc (OXB.L) (OXB), Inventiva (IVA), Biotest Aktiengesellschaft (BIO.F) (BIO), Aptose Biosciences (APS), Ergomed plc (ERGO.L) (ERGO), Burcon NutraScience Co. (BU.TO) (BU), Silence Therapeutics plc (SLN.L) (SLN), Pfenex (PFNX) and BioTime (BTX). View all of NBTX's competitors. Who are Nanobiotix's key executives? Nanobiotix's management team includes the following people: Mr. Laurent Levy, Co-Founder, Pres of the Exec. Board & CEO (Age 48)Mr. Philippe Mauberna, CFO & Member of the Exec. Board (Age 57)Ms. Anne-Juliette Hermant M.A., Chief People Officer & Member of Exec. Board (Age 48)Ms. Elsa Borghi, Head of Innovation & Drug DiscoveryProf. Para Prasad Ph.D., Co-Founder and Member of Scientific Board (Age 76)Mr. Earl J. Bergey Ph.d., Co-Founder (Age 66)Mr. Alain Dostie, Chief Operating OfficerMs. Noël Kurdi, Director of Investor RelationsMr. Brandon Owens, VP of Strategic Marketing & Corp. CommunicationMs. Sarah Gaubert, Head of Communication & Public Affairs Department When did Nanobiotix IPO? (NBTX) raised $95 million in an initial public offering on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont served as the underwriters for the IPO. What is Nanobiotix's stock symbol? Nanobiotix trades on the NASDAQ under the ticker symbol "NBTX." When did Nanobiotix's quiet period expire? Nanobiotix's quiet period expired on Wednesday, January 20th. Nanobiotix had issued 7,300,000 shares in its IPO on December 11th. The total size of the offering was $98,550,000 based on an initial share price of $13.50. During Nanobiotix's quiet period, insiders and any underwriters involved in the IPO were restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. What is Nanobiotix's stock price today? One share of NBTX stock can currently be purchased for approximately $19.00. How big of a company is Nanobiotix? Nanobiotix has a market capitalization of $633.46 million. Nanobiotix employs 98 workers across the globe. What is Nanobiotix's official website? The official website for Nanobiotix is www.nanobiotix.com. How can I contact Nanobiotix? The company can be reached via phone at 33 1 40 26 04 70. This page was last updated on 1/24/2021 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here
